Drug Trial Radar · NCT02851797
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Feb 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Jun 6, 2017
Primary completion
Feb 22, 2022
Study completion Feb 22, 2022
Sponsor
- Lead sponsor
- ItalfarmacoIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Aug 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective The primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects. Secondary Objectives The secondary objectives of this study were: * To assess the safety and tolerability of givinostat versus placebo administered chronically in DMD subjects * To evaluate the PK profile of givinostat administered chronically in DMD subjects * To evaluate the impact on quality of life (QoL) and activities of daily living of givinostat versus placebo administered chronically.
Conditions
- Duchenne Muscular Dystrophy
Interventions
givinostatDrug
The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below: Givinostat or placebo starting dose * \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid * \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid * \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid * \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid * \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid * \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid * \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid * \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid * \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid
placeboDrug
The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of TreatmentTime frame: Baseline and 18 months
Locations
42 sites in 11 countries. Site status is shown where the registry gives one.
Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation
Davis, California
Rady Children's Hospital center - UCSD Department of Neuroscience
San Diego, California
Children's Hospital Colorado
Aurora, Colorado
Connecticut Children's Medical Center - Division Neurology
Hartford, Connecticut
Child Health Research Institute - Department of Pediatrics
Gainesville, Florida
Nemours Children's Hospital
Orlando, Florida
MD Rare Disease Research, LLC
Atlanta, Georgia
University of Iowa Children's Hospital
Iowa City, Iowa
University of Minnesota - Department of Neurology
Minneapolis, Minnesota
Washington University School of Medicine in St Louis - Department of Neurology
St Louis, Missouri
Shriners Hospitals for Children
Portland, Oregon
The Children's Hospital of Philadelphia Colket Translational Research Building
Philadelphia, Pennsylvania
Virginia Commonwealth University Childrens Hospital of Richmond at Virginia Commonwealth University
Richmond, Virginia
University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology
Leuven, Belgium
Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)
Liège, Belgium
Kinsmen Research Centre - Alberta Children's Hospital - Alberta Health Services
Calgary, Alberta, Canada
The University of British Columbia, Children's and Womens Health Centre of BC Branch
Vancouver, British Columbia, Canada
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, Canada
CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest
Nantes, France
Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques
Paris, France
Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie
Essen, Germany
Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf
Hamburg, Germany
Klinikum der Uniersitat Munchen - Campus Innenstadt
München, Germany
Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14
Petah Tikva, Israel
IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative
Genova, Italy
A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari
Messina, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica
Milan, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Centro Clinico NeMO Fondazione Serena ONLUS Area SUD
Milan, Italy
Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative
Roma, Italy
Fondazione Policlinico Universitario "A.Gemelli", UOC Neuropsichiatria Infantile
Roma, Italy
Leiden University Medical Center LUMC
Leiden, Netherlands
Radboud University Medical Centre
Nijmegen, Netherlands
Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,
Belgrade, Serbia
Hospital Materno-Infantil - Passeig de la Vall d'Hebron
Barcelona, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitari i Politécnic de la Fe - Servicio Neurologia
Valencia, Spain
Hospital Sant Joan de Déu - Neuromuscular Pathology Unit
Esplugues de Llobregat, Barcelona, Spain
Alder Hey Children's Hospital NHS Trust
Liverpool, United Kingdom
UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD
London, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.